Is this a Prime Time To acquire DermTech Inc. (DMTK) stock

The price of DermTech Inc. (NASDAQ: DMTK) closed at $5.50 in the last session, down -1.61% from day before closing price of $5.59. In other words, the price has decreased by -$0.09 from its previous closing price. On the day, 1416133 shares were traded. DMTK stock price reached its highest trading level at $6.44 during the session, while it also had its lowest trading level at $5.27.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

We take a closer look at DMTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.40 and its Current Ratio is at 9.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On June 14, 2022, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $38 to $19.

On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $26.Stephens initiated its Overweight rating on January 07, 2022, with a $26 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 12 when Ibarra Claudia sold 328 shares for $2.22 per share. The transaction valued at 728 led to the insider holds 157,822 shares of the business.

Wood Todd Michael sold 356 shares of DMTK for $790 on Dec 12. The Chief Commercial Officer now owns 214,110 shares after completing the transaction at $2.22 per share. On Dec 08, another insider, Ibarra Claudia, who serves as the Chief Operating Officer of the company, sold 2,496 shares for $2.32 each. As a result, the insider received 5,791 and left with 158,150 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 10.85 while its Price-to-Book (P/B) ratio in mrq is 1.07.

Stock Price History:

Over the past 52 weeks, DMTK has reached a high of $16.33, while it has fallen to a 52-week low of $1.55. The 50-Day Moving Average of the stock is 2.59, while the 200-Day Moving Average is calculated to be 5.36.

Shares Statistics:

According to the various share statistics, DMTK traded on average about 778.82K shares per day over the past 3-months and 1.82M shares per day over the past 10 days. A total of 30.10M shares are outstanding, with a floating share count of 27.75M. Insiders hold about 2.30% of the company’s shares, while institutions hold 43.40% stake in the company. Shares short for DMTK as of Oct 13, 2022 were 2.84M with a Short Ratio of 2.55M, compared to 2.89M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 9.45% and a Short% of Float of 12.37%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.95 for the current quarter, with a high estimate of -$0.74 and a low estimate of -$1.01, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.7 and low estimates of -$1.02.

Analysts are recommending an EPS of between -$3.92 and -$4.02 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$3.7, with 7 analysts recommending between -$3.2 and -$4.02.

Revenue Estimates

According to 7 analysts, the current quarter’s revenue is expected to be $4.97M. It ranges from a high estimate of $6.8M to a low estimate of $4.1M. As of the current estimate, DermTech Inc.’s year-ago sales were $3.41M, an estimated increase of 45.70% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $5.94M, an increase of 87.70% over than the figure of $45.70% in the same quarter last year. There is a high estimate of $8.6M for the next quarter, whereas the lowest estimate is $4.3M.

A total of 7 analysts have provided revenue estimates for DMTK’s current fiscal year. The highest revenue estimate was $24M, while the lowest revenue estimate was $16.5M, resulting in an average revenue estimate of $18.98M. In the same quarter a year ago, actual revenue was $11.84M, up 60.30% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $32.08M in the next fiscal year. The high estimate is $45M and the low estimate is $25.8M. The average revenue growth estimate for next year is up 69.00% from the average revenue estimate for this year.